E138: Dapirolizumab for SLE (PHOENYCS-GO)
A new therapy for SLE! This one is a CD40-CD40L blocker, which has some nice new-things to inhibit. The study itself was a qualified success...
Radio and PodcastLive Radio & PodcastsHealth
The Evidence Based Rheumatology Podcast
A weekly podcast for physicians interested in evidence based medicine and rheumatology. Find the papers at ebrheum.com
Episodes
20 of 103 episodesE137: Obexelimab in IgG4-RD (INDIGO)
Another day, another B cell drug. This one adds an interesting option for IgG4-RD, offering a "maybe less efficacious maybe less toxic" path...
E136: Secukinumab in PMR (REPLENISH)
Big trial this week in the NEJM investigating the IL17 inhibitor secukinumab in PMR. Well worth a read, I would bet on FDA approval in the n...
E135: IL17 and a GLP1?
Really interesting study this week comparing the IL17 inhibitor ixekizumab WITH the GLP1 inhibitor tirzepatide to ixekizumab alone. Raises s...
E134: Brepocitinib in Dermatomyositis (VALOR)
Great trial this week looking at brepocitinib in dermatomyositis. Looks like a winner, expect it will be approved. Where it fits in our appr...
E133: Obinutuzumab for SLE (ALLEGORY)
Good RCT this week, investigating the CD20 B cell inhibitor obinutuzumab for SLE. Sign up for my newsletter if you would like to have a read...
E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)
Quick podcast this week about a nifty head to head study that I had previously missed. Worth reading if - like me - you're still trying to f...
E131: A Sham-Controlled Sham of a Trial: RESET-RA
Today I cover the recent publication of the RESET-RA study, which evaluated vagal nerve stimulation to treat rheumatoid arthritis. Have a li...
E130: Telitacicept for SLE
Surprisingly (unbelievably?) impressive RCT evaluating the Blys/APRIL inhibitor "telitacicept" for patients with SLE (mixed SLE and SLE-LN)....
E129: Long Term Routine Laboratory Monitoring in RA
Ever wonder how often you really need to check "monitoring" labs? If so then this is the podcast for you! Bryant England mentioned this duri...
E128: Nerandomilast for Autoimmune ILD (FIBRONEER-ILD)
Covering a very interesting study this week, which investiaged the PDE4B inhibitor nerandomilast for patients with progressive pulmonary fib...
E127: TNFs and All That CHF
Another episode looking into safety this week! Tackling that pesky issue of TNFs and CHF. Be sure to subscribe to my newsletter and check ou...
E126: Risk Signals, JAKs, and SELECTIVE-ity
Covering an interesting but ultimately disappointing post hoc study of multiple upadacitinib trials in RA. Initially some hope for clarity i...
E125: Adrenal Insufficiency after Stopping Prednisone
Interesting read this week - I cover a nifty little paper that presented data about adrenal insufficiency after stopping prednisolone, publi...
e124: MTX vs Pred for Pulmonary Sarcoidosis: PREDMETH Study
Interesting NEJM trial this week comparing methotrexate to prednisone for pulmonary sarcoidosis. Paper available here: https://www.nejm.org/...
E123: Upadacitinib for Giant Cell Arteritis: SELECT-GCA
Podcast this week about the recently published SELECT-GCA study, which evaluated the use of the janus kinase inhibitor upadacitinib (Rinvoq)...
E122: Guidelines for Maybe Diagnosing HLH
This week I cover another of my newsletters, though I mostly use it as a skeleton to riff on a common (and challenging) issue for rheumatolo...
E121: Obinutuzumab in SLE-LN
Another day, another b cell podcast. Seems to be all the rage! This week I discuss the recently published NEJM trial of the anti CD20 agent...
E120: Real Life Use of PEXIVAS-Low
What do you do when observational data and RCTs conflict? This week I'm covering the "real world PEXIVAS" study that was done by the French...
E119: Teclistamab for Rheumatology Writ Large
One of my rare case-report podcasts, a topic that I typically avoid. The craze about CAR-T has also made me a little crazy, though, so I wan...